Changes to the Code
H.R. 9192 · Prior Authorization Reform for Autoimmune and Blood Disorders Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
26 U.S.C. § 9827 Requirements with respect to coverage of drugs for autoimmune diseases and certain blood disorders New section
1 change the bill asks for here, 1 carried out
- Carried out:
Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:9827. Requirements with respect to coverage of drugs for autoimmune diseases and certain blood disorders (a) In general.— A group health plan— (1) shall provide coverage for any drug that is an autoimmune or blood disorder drug, without regard to whether such drug is dispensed by a pharmacy or furnished incident to another item or service for which benefits are available under such plan; and (2) may not require, with respect to an individual enrolled under such plan, that prior authorization for such a drug be obtained more than once during any 12-month period unless such drug is— (A) typically used for a period of 12 months or less; (B) an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or (C) a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act. (b) Autoimmune or blood disorder drug defined.— In this section, the term
autoimmune or blood disorder drug
means a drug or biological product that is indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease..
§ 9827(a)–(b)
§ 9827. [inserted: Requirements with respect to coverage of drugs for autoimmune diseases and certain blood disorders]
(a) [inserted: In general.—] [inserted: A group health plan—]
(1) [inserted: shall provide coverage for any drug that is an autoimmune or blood disorder drug, without regard to whether such drug is dispensed by a pharmacy or furnished incident to another item or service for which benefits are available under such plan; and]
(2) [inserted: may not require, with respect to an individual enrolled under such plan, that prior authorization for such a drug be obtained more than once during any 12-month period unless such drug is—]
(A) [inserted: typically used for a period of 12 months or less;]
(B) [inserted: an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or]
(C) [inserted: a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act.]
(b) [inserted: Autoimmune or blood disorder drug defined.—] [inserted: In this section, the term “autoimmune or blood disorder drug” means a drug or biological product that is indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.]